دورية أكاديمية
أعرض في EDS

Olfactory neuronal cells as a promising tool to realize the "druggable genome" approach for drug discovery in neuropsychiatric disorders.

التفاصيل البيبلوغرافية
العنوان: Olfactory neuronal cells as a promising tool to realize the "druggable genome" approach for drug discovery in neuropsychiatric disorders.
المؤلفون: Mihaljevic M; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Lam M; IMH Neuropsychiatric Genomics Laboratory, Institute of Mental Health, Singapore, Singapore.; Population and Global Health, LKC Medicine, Nanyang Technological University, Singapore, Singapore.; Neurogenomic Biomarkers Laboratory, Zucker Hillside Hospital, Glen Oaks, NY, United States.; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, United States., Ayala-Grosso C; Unit of Cellular Therapy, Centre of Experimental Medicine, Instituto Venezolano de Investigaciones Cientificas IVIC, Caracas, Venezuela., Davis-Batt F; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Schretlen DJ; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Ishizuka K; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Yang K; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Sawa A; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
المصدر: Frontiers in neuroscience [Front Neurosci] 2023 Mar 10; Vol. 16, pp. 1081124. Date of Electronic Publication: 2023 Mar 10 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101478481 Publication Model: eCollection Cited Medium: Print ISSN: 1662-4548 (Print) Linking ISSN: 1662453X NLM ISO Abbreviation: Front Neurosci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Research Foundation
مستخلص: "Druggable genome" is a novel concept that emphasizes the importance of using the information of genome-wide genetic studies for drug discovery and development. Successful precedents of "druggable genome" have recently emerged for some disorders by combining genomic and gene expression profiles with medical and pharmacological knowledge. One of the key premises for the success is the good access to disease-relevant tissues from "living" patients in which we may observe molecular expression changes in association with symptomatic alteration. Thus, given brain biopsies are ethically and practically difficult, the application of the "druggable genome" approach is challenging for neuropsychiatric disorders. Here, to fill this gap, we propose the use of olfactory neuronal cells (ONCs) biopsied and established via nasal biopsy from living subjects. By using candidate genes that were proposed in a study in which genetic information, postmortem brain expression profiles, and pharmacological knowledge were considered for cognition in the general population, we addressed the utility of ONCs in the "druggable genome" approach by using the clinical and cell resources of an established psychosis cohort in our group. Through this pilot effort, we underscored the chloride voltage-gated channel 2 (CLCN2) gene as a possible druggable candidate for early-stage psychosis. The CLCN2 gene expression was associated with verbal memory, but not with other dimensions in cognition, nor psychiatric manifestations (positive and negative symptoms). The association between this candidate molecule and verbal memory was also confirmed at the protein level. By using ONCs from living subjects, we now provide more specific information regarding molecular expression and clinical phenotypes. The use of ONCs also provides the opportunity of validating the relationship not only at the RNA level but also protein level, leading to the potential of functional assays in the future. Taken together, we now provide evidence that supports the utility of ONCs as a tool for the "druggable genome" approach in translational psychiatry.
Competing Interests: Under an agreement with Psychological Assessment Resources, Inc., DS is entitled to a share of royalty on sales of a test used in the study described in this article. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Mihaljevic, Lam, Ayala-Grosso, Davis-Batt, Schretlen, Ishizuka, Yang and Sawa.)
References: Sci Rep. 2018 Feb 21;8(1):3434. (PMID: 29467471)
Mol Psychiatry. 2015 Jul;20(7):820-6. (PMID: 25869805)
Am J Physiol Cell Physiol. 2004 Nov;287(5):C1173-83. (PMID: 15213059)
Hum Mol Genet. 2018 Sep 15;27(18):3165-3176. (PMID: 29893844)
Schizophr Res. 2021 Sep;235:9-11. (PMID: 34280869)
Schizophr Bull. 2018 Apr 6;44(3):672-680. (PMID: 28981913)
Sci Adv. 2019 Sep 11;5(9):eaau4139. (PMID: 31535015)
JAMA Psychiatry. 2019 Mar 1;76(3):314-323. (PMID: 30624573)
Mol Autism. 2014 Jan 10;5(1):1. (PMID: 24410847)
Mod Probl Pharmacopsychiatry. 1990;24:73-88. (PMID: 2336066)
Neurosci Biobehav Rev. 2021 Jul;126:265-275. (PMID: 33812977)
Nat Genet. 2018 Aug;50(8):1112-1121. (PMID: 30038396)
Neurosci Biobehav Rev. 2011 Jan;35(3):573-88. (PMID: 20620163)
Nat Rev Drug Discov. 2002 Sep;1(9):727-30. (PMID: 12209152)
Neuron. 2023 Jan 18;111(2):220-235.e9. (PMID: 36379214)
Biol Psychiatry. 2013 Sep 15;74(6):418-26. (PMID: 23482246)
Nat Protoc. 2016 Sep;11(9):1650-67. (PMID: 27560171)
Am J Physiol Cell Physiol. 2014 Sep 1;307(5):C479-92. (PMID: 25009109)
Schizophr Bull. 1999;25(2):233-55. (PMID: 10416729)
Neurosci Res. 2013 Dec;77(4):247-50. (PMID: 24120685)
Neurosci Res. 2022 Mar;176:79-84. (PMID: 34655664)
Mol Psychiatry. 2016 Sep;21(9):1215-24. (PMID: 26239292)
Lancet Neurol. 2013 Jul;12(7):659-68. (PMID: 23707145)
Nat Commun. 2019 May 1;10(1):2068. (PMID: 31043617)
Neuropsychopharmacology. 2021 Sep;46(10):1788-1801. (PMID: 34035472)
Curr Opin Pharmacol. 2020 Apr;51:78-92. (PMID: 31982325)
Sci Adv. 2018 Dec 13;4(12):eaav8550. (PMID: 30555922)
Nat Genet. 2009 Sep;41(9):954-5. (PMID: 19710712)
NPJ Parkinsons Dis. 2018 Mar 16;4:6. (PMID: 29560414)
Neurobiol Dis. 2013 Jul;55:1-10. (PMID: 23542694)
Trends Mol Med. 2017 Feb;23(2):100-103. (PMID: 28108112)
Schizophr Res. 2019 Jun;208:49-54. (PMID: 30987924)
FASEB J. 2021 Jul;35(7):e21689. (PMID: 34085737)
Schizophr Res. 2021 Dec;238:99-107. (PMID: 34649085)
Nat Commun. 2021 Dec 20;12(1):7342. (PMID: 34930919)
Mol Psychiatry. 2021 Aug;26(8):3931-3942. (PMID: 33173197)
Nat Med. 2021 Apr;27(4):668-676. (PMID: 33837377)
Arch Gen Psychiatry. 1992 Aug;49(8):630-6. (PMID: 1637253)
J Biol Chem. 2021 Jan-Jun;296:100074. (PMID: 33187987)
F1000Res. 2018 Aug 24;7:1338. (PMID: 30254741)
BMC Neurol. 2019 Jul 10;19(1):156. (PMID: 31291907)
Schizophr Bull. 2021 Aug 21;47(5):1243-1253. (PMID: 33761534)
Nat Genet. 2021 Jan;53(1):35-44. (PMID: 33414549)
Nat Genet. 2017 Mar;49(3):416-425. (PMID: 28166213)
Biol Psychiatry. 2020 Aug 1;88(3):236-247. (PMID: 32143829)
Commun Biol. 2021 Jun 8;4(1):700. (PMID: 34103634)
Int J Mol Sci. 2021 Aug 25;22(17):. (PMID: 34502103)
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):. (PMID: 35074870)
Mol Psychiatry. 2021 Jul;26(7):3502-3511. (PMID: 33077854)
Schizophr Bull. 2016 Jul;42 Suppl 1:S90-4. (PMID: 27460622)
CNS Drugs. 2021 Dec;35(12):1265-1274. (PMID: 34427901)
Clin Neuropsychol. 2009 Aug;23(6):926-43. (PMID: 19191072)
Mol Psychiatry. 2022 Feb;27(2):1184-1191. (PMID: 34642460)
Transl Psychiatry. 2015 Oct 20;5:e663. (PMID: 26485547)
Mol Psychiatry. 2021 Aug;26(8):4004-4015. (PMID: 31628418)
Transl Psychiatry. 2022 Mar 10;12(1):99. (PMID: 35273151)
Mol Psychiatry. 2013 Jul;18(7):740-2. (PMID: 22925834)
معلومات مُعتمدة: P50 MH094268 United States MH NIMH NIH HHS; R01 MH092443 United States MH NIMH NIH HHS; R01 MH105660 United States MH NIMH NIH HHS; R01 MH107730 United States MH NIMH NIH HHS
فهرسة مساهمة: Keywords: CLCN2; cognition; drug discovery; nalas biopsy; olfactory neuronal cells; psychosis
تواريخ الأحداث: Date Created: 20230327 Latest Revision: 20240509
رمز التحديث: 20240509
مُعرف محوري في PubMed: PMC10038100
DOI: 10.3389/fnins.2022.1081124
PMID: 36967982
قاعدة البيانات: MEDLINE
الوصف
تدمد:1662-4548
DOI:10.3389/fnins.2022.1081124